Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial
revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as
Novartis’s Gleevec/Glivec [imatinib]), significant unmet needs remain because certain segments of the CML
patient population are intolerant of or become resistant to existing therapies. Emerging therapies that focus on
the unmet needs of current therapeutics have a good chance of replicating Gleevec’s success.
Questions Answered in This Report
Properly diagnosing CML is an integral part of choosing an effective treatment. How is CML diagnosed?
What role does genetic testing play in developing and deploying drugs for CML? What are the
symptoms of CML?
Treatment options for CML are more targeted today than in recent history. How was CML previously
treated? Why have targeted therapies proved to be better CML treatment options?
Despite treatment advances, opportunities remain for emerging CML agents. What are these
opportunities? Are the opportunities potentially lucrative enough to motivate drug developers?
Scope
Disease overview: disease causes and indicators, physical and genetic symptoms, diagnosis,
classification, epidemiology, and disease progression.
Current CML therapies: chemotherapy, interferon-alpha, targeted therapies, stem cell therapy.
(0 items)
